Use of nanoparticles coated with red blood cell membranes to treat hemolytic diseases and disorders
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11110127-B2
Publication Date
2021-09-07
Expiration Date
Abstract
The present invention relates to methods, combinations and pharmaceutical compositions for treating or preventing a hemolytic disease or condition in a mammal, wherein: said hemolytic disease or condition is caused by an attack of said mammal's red blood cells by said mammal's own body, or said mammal is a pregnant mammal and said hemolytic disease or condition of a fetus of said pregnant mammal is caused by an attack of said fetus' red blood cells by an antibody of said pregnant mammal, or said mammal is a baby and said hemolytic disease or condition of said baby is caused by an attack of said baby's red blood cells by an antibody of said baby's mother. The exemplary hemolytic diseases or conditions include hemophagocytic lymphohistiocytosis, an autoimmune disease or condition, or a hereditary hemolytic disease or disorder.
Core Innovation
The invention relates to reducing antibody attack in a mammal by administering an effective amount of a nanoparticle. The nanoparticle comprises an inner core comprising a material selected from PLGA, PLA, PGA, PCL, polylysine, and polyglutamic acid, and an outer surface comprising a plasma membrane derived from a red blood cell.
The method is directed to a pregnant mammal in which the pregnant mammal’s antibody attacks her fetus’ red blood cells, and to a baby in which the baby’s red blood cells are attacked by an antibody of the baby’s mother. The antibodies include anti-A, anti-B, anti-rhesus D, anti-rhesus E, anti-rhesus c, anti-rhesus e, anti-rhesus C, anti-Kell, anti-Lewis, anti-Duffy, anti-Kidd, anti-P, anti-MN, or combinations thereof.
The nanoparticle concept includes using a red-blood-cell-membrane-derived outer surface as a decoy for red blood cells in order to reduce hemolytic disease or condition caused by attack of red blood cells. Embodiments described in the partial content include limiting immunogenicity by reducing red blood cell membrane constituents and/or hemoglobin, maintaining natural structural integrity of a cellular/red blood cell membrane, and optionally including releasable cargo while remaining biocompatible and biodegradable.
Claims Coverage
The independent claim recites a method for reducing antibody attack by administering a red-blood-cell-plasma-membrane-coated nanoparticle having a specified inner core polymer set and specified antibody targets, for two maternal-fetal/infant contexts. The inventive features below are the main structural and use limitations present in the independent claim.
Administering a nanoparticle with a specified inner core polymer
Administering, to a mammal in need of the reduction, an effective amount of a nanoparticle having an inner core comprising a material selected from PLGA, PLA, PGA, PCL, polylysine, and polyglutamic acid.
Using a red-blood-cell-derived plasma membrane outer surface
The nanoparticle has an outer surface comprising a plasma membrane derived from a red blood cell.
Reducing antibody attack in a pregnant mammal or an antibody-exposed baby
The mammal is a pregnant mammal and the pregnant mammal’s antibody attacks her fetus’ red blood cells, or the mammal is a baby and the baby’s red blood cells are attacked by an antibody of the baby’s mother.
Targeting specified anti-blood-group antibodies
The antibody attacking is an anti-A, anti-B, anti-rhesus D, anti-rhesus E, anti-rhesus c, anti-rhesus e, anti-rhesus C, anti-Kell, anti-Lewis, anti-Duffy, anti-Kidd, anti-P, anti-MN, or combinations thereof.
Overall, the claim coverage centers on the combination of a specified inner core polymer set, a red-blood-cell-derived plasma membrane outer surface, and reducing antibody attack in a pregnant/fetal or mother-to-infant antibody context involving specified anti-blood-group antibodies.
Stated Advantages
Reduces antibody attack in a mammal.
Reduces hemolytic disease or condition caused by attack of red blood cells.
Uses the red-blood-cell-membrane-derived outer surface as a decoy for red blood cells.
Documented Applications
Maternal-fetal cases where a pregnant mammal’s antibody attacks her fetus’ red blood cells, including antibody specificities listed in the claim.
Infant/baby cases where a baby’s red blood cells are attacked by an antibody of the baby’s mother.
Hemolytic diseases/conditions caused by attack of red blood cells.
Interested in licensing this patent?